

**EDWARDS LIFESCIENCES CORPORATION**  
**Reconciliation of GAAP to Non-GAAP Financial Information**

(in millions, except per share data)	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2008	2007	2008	2007
<b>GAAP net income</b>	\$39.7	\$34.9	\$57.9	\$68.1
<b>Reconciling items:</b>				
<b>Special (gains) charges, net</b>				
1) Loss on sale of product line	-	-	8.1	-
2) Litigation settlement	-	-	2.1	-
3) Realignment expenses, net	(0.8)	-	(0.9)	-
Total special (gains) charges, net	(0.8)	-	9.3	-
<b>Provision for income taxes</b>				
Tax effect on non-GAAP adjustments (A)	0.1	-	5.0	-
Total provision for income taxes, net	0.1	-	5.0	-
<b>Non-GAAP net income</b>	<b>\$39.0</b>	<b>\$34.9</b>	<b>\$72.2</b>	<b>\$68.1</b>
<b>Non-GAAP earnings per share:</b>				
Basic non-GAAP earnings per share	\$0.70	\$0.61	\$1.29	\$1.18
Diluted non-GAAP earnings per share (B)	\$0.66	\$0.57	\$1.22	\$1.11
<b>Non-GAAP weighted average shares outstanding:</b>				
Basic	55.4	57.5	55.8	57.7
Diluted	60.2	63.0	60.7	63.2

Notes 1 - 3: See description of Special (Gains) Charges, net on the previous page.

(A) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdictions' statutory tax rates.

(B) Diluted non-GAAP earnings per share is calculated by adding back to net income \$0.7 million for the quarter in interest expense related to the convertible debt, and \$1.7 million for the six month period, then dividing by the weighted average diluted shares outstanding.

Note: Numbers may not calculate due to rounding